Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production

Journal of Neurochemistry

Volumn 128, Issue 2, 2014, Pages 330-339

  Suárez Calvet, Marc ^a,b,c   Belbin, Olivia ^a,b,c   Pera, Marta ^a,b,c   Badiola, Nahuai ^a,b,c   Magrané, Jordi ^d   Guardia Laguarta, Cristina ^a,b,c   Muñoz, Laia ^a,b,c   Colom Cadena, Martí ^a,b,c   Clarimõn, Jordi ^a,b,c   Lleõ, Alberto ^a,b,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c Hospital de la Santa   (Spain)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

secretase; Alzheimer's disease; amyloid peptide; APP mutations; presenilin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; PRESENILIN 1;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; AUTOSOMAL DOMINANT ALZHEIMER DISEASE; AUTOSOMAL DOMINANT DISORDER; CELL MEMBRANE; CELL STRAIN CHO K1; CHO CELL; CODON; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GLIOMA CELL; HUMAN; HUMAN CELL; NEUROGLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PROCESSING; PSEN1 GENE;

ALZHEIMER'S DISEASE; AMYLOID-Β PEPTIDE; APP MUTATIONS; PRESENILIN; Γ-SECRETASE;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CHO CELLS; CODON; CRICETINAE; CRICETULUS; HUMANS; MUTATION;

EID: 84891834844     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12466     Document Type: Article

References (50)

1. Bateman R. J., Aisen P. S., De Strooper B., et al,. (2011) Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1.
2. Borgegard T., Gustavsson S., Nilsson C., et al,. (2012) Alzheimer's disease: presenilin 2-sparing gamma-secretase inhibition is a tolerable Abeta peptide-lowering strategy. J. Neurosci. 32, 17297-17305.
3. Campion D., Dumanchin C., Hannequin D., et al,. (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664-670.
4. Chavez-Gutierrez L., Bammens L., Benilova I., et al,. (2012) The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261-2274.
5. Cruts M., Theuns J., and, Van Broeckhoven C., (2012) Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 33, 1340-1344.
6. De Jonghe C., Esselens C., Kumar-Singh S., Craessaerts K., Serneels S., Checler F., Annaert W., Van Broeckhoven C., and, De Strooper B., (2001) Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect A beta secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10, 1665-1671.
7. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., and, Van Leuven F., (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390.
8. Eckman C. B., Mehta N. D., Crook R., et al,. (1997) A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum. Mol. Genet. 6, 2087-2089.
9. Eckman E. A., Reed D. K., and, Eckman C. B., (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276, 24540-24548.
10. Edwards-Lee T., Ringman J. M., Chung J., et al,. (2005) An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 64, 377-379.
11. Forloni G., Terreni L., Bertani I., et al,. (2002) Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol. Aging 23, 957-976.
12. Franberg J., Svensson A. I., Winblad B., Karlstrom H., and, Frykman S., (2011) Minor contribution of presenilin 2 for gamma-secretase activity in mouse embryonic fibroblasts and adult mouse brain. Biochem. Biophys. Res. Commun. 404, 564-568.
13. Fraser P. E., Nguyen J. T., Inouye H., Surewicz W. K., Selkoe D. J., Podlisny M. B., and, Kirschner D. A., (1992) Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry 31, 10716-10723.
14. Games D., Adams D., Alessandrini R., et al,. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527.
15. Goate A., Chartier-Harlin M. C., Mullan M., et al,. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
16. Groves J. T., Parthasarathy R., and, Forstner M. B., (2008) Fluorescence imaging of membrane dynamics. Annu. Rev. Biomed. Eng. 10, 311-338.
17. Guardia-Laguarta C., Pera M., Clarimon J., et al,. (2010) Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J. Neuropathol. Exp. Neurol. 69, 53-59.
18. Guerreiro R. J., Baquero M., Blesa R., et al,. (2010) Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol. Aging 31, 725-731.
19. Haass C., Koo E. H., Mellon A., Hung A. Y., and, Selkoe D. J., (1992) Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500-503.
20. Haass C., Lemere C. A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L., and, Selkoe D. J., (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat. Med. 1, 1291-1296.
21. Haass C., Kaether C., Thinakaran G., and, Sisodia S., (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270.
22. Herl L., Thomas A. V., Lill C. M., Banks M., Deng A., Jones P. B., Spoelgen R., Hyman B. T., and, Berezovska O., (2009) Mutations in amyloid precursor protein affect its interactions with presenilin/gamma-secretase. Mol. Cell. Neurosci. 41, 166-174.
23. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and, Ihara Y., (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end- specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45-53.
24. Janssen J. C., Beck J. A., Campbell T. A., Dickinson A., Fox N. C., Harvey R. J., Houlden H., Rossor M. N., and, Collinge J., (2003) Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 60, 235-239.
25. Jiang Y., Mullaney K. A., Peterhoff C. M., et al,. (2010) Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl Acad. Sci. USA 107, 1630-1635.
26. Kim H. S., Kim E. M., Lee J. P., et al,. (2003) C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J. 17, 1951-1953.
27. Kumar-Singh S., De Jonghe C., Cruts M., et al,. (2000) Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum. Mol. Genet. 9, 2589-2598.
28. Lauritzen I., Pardossi-Piquard R., Bauer C., et al,. (2012) The beta-secretase-derived C-terminal fragment of betaAPP, C99, but not Abeta, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 32, 16243-16255a.
29. Lichtenthaler S. F., Wang R., Grimm H., Uljon S. N., Masters C. L., and, Beyreuther K., (1999) Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 96, 3053-3058.
30. Lleo A., and, Saura C. A., (2011) Gamma-secretase substrates and their implications for drug development in Alzheimer's disease. Curr. Top. Med. Chem. 11, 1513-1527.
31. Lleo A., Berezovska O., Growdon J. H., and, Hyman B. T., (2004) Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am. J. Geriatr. Psychiatry 12, 146-156.
32. Magrane J., Sahawneh M. A., Przedborski S., Estevez A. G., and, Manfredi G., (2012) Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32, 229-242.
33. McPhie D. L., Lee R. K., Eckman C. B., Olstein D. H., Durham S. P., Yager D., Younkin S. G., Wurtman R. J., and, Neve R. L., (1997) Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains. J. Biol. Chem. 272, 24743-24746.
34. Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K., and, Matsuoka N., (2012) Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 2037-2050.
35. Morelli L., Llovera R., Gonzalez S. A., Affranchino J. L., Prelli F., Frangione B., Ghiso J., and, Castano E. M., (2003) Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem. 278, 23221-23226.
36. Nilsberth C., Westlind-Danielsson A., Eckman C. B., et al,. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887-893.
37. Oster-Granite M. L., McPhie D. L., Greenan J., and, Neve R. L., (1996) Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 16, 6732-6741.
38. Page R. M., Gutsmiedl A., Fukumori A., Winkler E., Haass C., and, Steiner H., (2010) Beta-amyloid precursor protein mutants respond to gamma-secretase modulators. J. Biol. Chem. 285, 17798-17810.
39. Pera M., Alcolea D., Sanchez-Valle R., et al,. (2012) Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 125, 201-213.
40. Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y., et al,. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 25, 436-445.
41. Raux G., Guyant-Marechal L., Martin C., Bou J., Penet C., Brice A., Hannequin D., Frebourg T., and, Campion D., (2005) Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J. Med. Genet. 42, 793-795.
42. Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., Condron M. M., Teplow D. B., and, Haass C., (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2, 835-841.
43. Sato T., Dohmae N., Qi Y., et al,. (2003) Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J. Biol. Chem. 278, 24294-24301.
44. Saura C. A., Chen G., Malkani S., et al,. (2005) Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J. Neurosci. 25, 6755-6764.
45. Schneider C. A., Rasband W. S., and, Eliceiri K. W., (2012) NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675.
46. Tan J., Mao G., Cui M. Z., Kang S. C., Lamb B., Wong B. S., Sy M. S., and, Xu X., (2008) Effects of gamma-secretase cleavage-region mutations on APP processing and Abeta formation: interpretation with sequential cleavage and alpha-helical model. J. Neurochem. 107, 722-733.
47. Tsubuki S., Takaki Y., and, Saido T. C., (2003) Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361, 1957-1958.
48. Vom Berg J., Prokop S., Miller K. R., et al,. (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18, 1812-1819.
49. Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., and, Neve R. L., (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-420.
50. Zekanowski C., Styczynska M., Peplonska B., et al,. (2003) Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp. Neurol. 184, 991-996.